Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
FDF
0
FDA Orange Book
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Weekly News Recap #Phispers
1. Chenyl Taurine Sodium
2. Tauroursodeoxycholate
3. Tauroursodeoxycholate Sodium Salt
4. Tauroursodeoxycholic Acid, (3alpha,5alpha,7alpha)-isomer
5. Tauroursodeoxycholic Acid, Monosodium Salt, (3alpha,5beta,7alpha)-isomer
6. Taurursodiol
7. Tudca
8. Ursodoxicoltaurine
1. 14605-22-2
2. Tudca
3. Ursodeoxycholyltaurine
4. Tauroursodeoxycholate
5. Taurursodiol
6. Taurolite
7. Ursodoxicoltaurine
8. Ur 906
9. Sodium Tauroursodeoxycholate
10. Tauroursodesoxycholic Acid
11. Ursodeoxy Cholic Acid
12. Taurursodiol [usan]
13. 60eux8mn5x
14. Chembl272427
15. Chebi:80774
16. Ur-906
17. Taurursodiol (usan)
18. Ursodoxicoltaurine (inn)
19. Ursodoxicoltaurine [inn]
20. N-(3alpha,7beta-dihydroxy-5beta-cholan-24-oyl)-taurine
21. Tauroursodeoxycholate Sodium
22. 2-[(4r)-4-[(1s,2s,5r,7s,9s,10r,11s,14r,15r)-5,9-dihydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl]pentanamido]ethane-1-sulfonic Acid
23. 2-{[(3alpha,5beta,7alpha,8alpha,14beta,17alpha)-3,7-dihydroxy-24-oxocholan-24-yl]amino}ethanesulfonic Acid
24. Unii-60eux8mn5x
25. N-(3alpha,7beta-dihydroxy-5beta-cholan-24-oyl)taurine
26. Mfcd00065451
27. Tuda
28. N-ursodeoxycholoyltaurine
29. Tauroursodeoxycholic Acid, Sodium Salt
30. Schembl40764
31. Gtpl4746
32. Tauroursodeoxycholic Acid;tudca
33. Dtxsid80932754
34. Ex-a730
35. 2-(((3-alpha,5-beta,7-beta)-3,7-dihydroxy-24-oxocholan-24-yl) Amino)ethanesulfonic Acid
36. Hms3885c19
37. Ursodoxicoltaurine [who-dd]
38. Taurine, N-(3-alpha,7-beta-dihydroxy-5-beta-cholan-24-oyl)-,
39. Zinc3914813
40. 3alpha,7beta-dihydroxy-5beta-cholan-24-oic Acid N-(2-sulfoethyl)amide
41. Bdbm50236230
42. Lmst05040015
43. S3654
44. Sodium Tauroursodeoxycholate, >=95%
45. Who 11388
46. Ccg-269687
47. Db08834
48. 2-(((3-alpha,5-beta,7-beta)-3,7-dihydroxy-24-oxocholan-24-yl)amino)ethanesulfonic Acid
49. Ac-34539
50. Hy-19696
51. Cs-0016289
52. T1567
53. 3alpha,7beta-dihydroxy-5beta-cholanoyltaurine
54. D11836
55. 605t222
56. A808445
57. Q7688907
58. 3,7-dihydroxy-n-(2-sulfoethyl)cholan-24-imidic Acid
59. 3.alpha.,7.beta.-dihydroxy-5.beta.-cholanoyltaurine
60. 2-[(3alpha,7beta-dihydroxy-24-oxo-5beta-cholan-24-yl)amino]ethanesulfonic Acid
61. 2-{[(3alpha,5beta,7beta)-3,7-dihydroxy-24-oxocholan-24-yl]amino}ethane-1-sulfonic Acid
62. Ethanesulfonic Acid,2-[[(3a,5b,7b)-3,7-dihydroxy-24-oxocholan-24-yl]amino]-
63. 2-((r)-4-((3r,5s,7s,8r,9s,10s,13r,14s,17r)-3,7-dihydroxy-10,13-dimethyl-hexadecahydro-1h-cyclopenta[a]phenanthren-17-yl)pentanamido)ethanesulfonic Acid
64. 2-[[(4r)-4-[(3r,5s,7s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-3,7-bis(oxidanyl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonic Acid
65. 2-[[(4r)-4-[(3r,5s,7s,8r,9s,10s,13r,14s,17r)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-1-oxopentyl]amino]ethanesulfonic Acid
66. Ethanesulfonic Acid, 2-(((3-alpha,5-beta,7-beta)-3,7-dihydroxy-24-oxocholan-24-yl)amino)-
| Molecular Weight | 499.7 g/mol |
|---|---|
| Molecular Formula | C26H45NO6S |
| XLogP3 | 3.6 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 7 |
| Exact Mass | 499.29675933 g/mol |
| Monoisotopic Mass | 499.29675933 g/mol |
| Topological Polar Surface Area | 132 Ų |
| Heavy Atom Count | 34 |
| Formal Charge | 0 |
| Complexity | 858 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 10 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Used in the treatment of cholesterol gallstones. Tauroursodeoxycholic acid is also being investigated for use in several conditions such as Primary Biliary Cirrhosis (PBC), insulin resistance, amyloidosis, Cystic Fibrosis, Cholestasis, and Amyotrophic Lateral Sclerosis.
Antiviral Agents
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)
Cholagogues and Choleretics
Gastrointestinal agents that stimulate the flow of bile into the duodenum (cholagogues) or stimulate the production of bile by the liver (choleretic). (See all compounds classified as Cholagogues and Choleretics.)
Tauroursodeoxycholic acid is the more hydrophilic form of ursodeoxycholic acid, which is naturally produced in the body. In patients with properly functioning gallbladders, both of these bile acids inhibit liver cholesterol secretion and synthesis as well as intestinal cholesterol absorption allowing for the promotion of cholesterol gallstone dissolution. The mechanism of action of tauroursodeoxycholic acid in the other conditions is still being investigated.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
STOCK RECAP #PipelineProspector
NEWS #PharmaBuzz
Global Sales Information
Market Place
ANALYTICAL
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
